Diabetes - Pipeline Insight, 2024

This “Diabetes - Pipeline Insight, 2024” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Diabetes: Understanding

Diabetes: Overview

Diabetes is a chronic metabolic disorder characterized by high blood sugar levels due to the body's inability to produce or effectively use insulin, a hormone essential for regulating glucose. The disease primarily exists in two main forms: Type 1 diabetes, an autoimmune condition where the immune system attacks insulin-producing cells in the pancreas, and Type 2 diabetes, which is more common and often associated with insulin resistance and lifestyle factors such as obesity and poor diet. Other types include gestational diabetes, which occurs during pregnancy, and rarer forms such as Maturity-Onset Diabetes of the Young (MODY) and Latent Autoimmune Diabetes in Adults (LADA).

The signs and symptoms of diabetes can vary depending on the type and severity of the condition but generally include increased thirst and frequent urination, as the body tries to flush out excess glucose from the blood. Other common symptoms are extreme hunger, unexpected weight loss, fatigue, and blurred vision due to fluctuating blood sugar levels. Slow-healing sores, frequent infections, and tingling or numbness in the hands and feet are also prevalent, particularly in Type 2 diabetes, indicating nerve damage.

The pathophysiology of diabetes involves disruptions in the body's ability to regulate blood glucose, primarily due to issues with insulin production or function. In Type 1 diabetes, an autoimmune response mistakenly targets and destroys the insulin-producing beta cells in the pancreas, leading to little or no insulin production. Without insulin, glucose cannot enter cells for energy, resulting in elevated blood sugar levels. In Type 2 diabetes, the body’s cells become resistant to insulin, and the pancreas fails to produce enough insulin to compensate for this resistance. This leads to a gradual rise in blood glucose levels.

Chronic hyperglycemia associated with both types of diabetes causes damage to blood vessels, nerves, and various organs over time, contributing to complications like cardiovascular disease, neuropathy, retinopathy, and nephropathy. The interplay of genetic, environmental, and lifestyle factors further influences the onset and progression of both forms of the disease.

The treatment of diabetes focuses on managing blood sugar levels through a combination of lifestyle changes, medication, and monitoring to prevent complications. For Type 1 diabetes, insulin therapy is essential since the body cannot produce insulin, and this can be administered via injections or an insulin pump. Type 2 diabetes management often begins with lifestyle modifications, including a balanced diet, regular physical activity, and weight loss, which can improve insulin sensitivity. If these measures are insufficient, oral medications like metformin or other drugs that increase insulin production or improve its effectiveness may be prescribed. 

"Diabetes- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetes pipeline landscape is provided which includes the disease overview and Diabetes treatment guidelines. The assessment part of the report embraces, in depth Diabetes commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetes collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Diabetes R&D. The therapies under development are focused on novel approaches to treat/improve Diabetes.

Diabetes Emerging Drugs Chapters

This segment of the Diabetes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Diabetes Emerging Drugs

Cadisegliatin: vTv Therapeutics

Cadisegliatin, also known as TTP399, is an innovative oral medication developed by vTv Therapeutics, designed as a liver-selective glucokinase activator. It aims to serve as an adjunctive therapy to insulin for individuals with type 1 diabetes (T1D). This drug has been recognized for its potential to improve glycemic control by enhancing hepatic glucose uptake and glycogen storage independently of insulin, addressing a critical need in diabetes management. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Diabetes.

LY-3209590: Eli Lilly and Company

Insulin efsitora alfa (LY3209590) is a once-weekly basal insulin, a fusion protein that combines a novel single-chain variant of insulin with a human IgG2 Fc domain. It is specifically designed for once-weekly subcutaneous administration, and with its low peak-to-trough ratio, it has the potential to provide more stable glucose levels (less glucose variability) throughout the week. Efsitora is in phase III development for adults with type 1 and 2 diabetes.

THDB0206: Tonghua Dongbao Pharmaceutical

BC Lispro (THDB0206) is an ultra-rapid-acting insulin analog developed by Tonghua Dongbao Pharmaceutical Co., Ltd. for the treatment of Diabetes. BC Lispro is designed to restore early-phase insulin secretion, which is often impaired in diabetic patients. This insulin analog utilizes a new formulation technology that allows for rapid absorption and action, mimicking the physiological pattern of insulin secretion after meals. Such characteristics are expected to reduce the risk of late postprandial hypoglycemia, providing patients with greater flexibility in managing their insulin injections. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Diabetes.

CPL207280: Celon Pharma

CPL207280 is a novel G-protein-coupled receptor 40 (GPR40) agonist under development for the treatment of Diabetes. CPL207280 acts as an agonist for GPR40, a receptor that plays a crucial role in enhancing glucose-stimulated insulin secretion from pancreatic beta cells. This mechanism is particularly beneficial for T2D patients, as it can improve glycemic control without the risk of hypoglycemia, a common side effect associated with other diabetes medications. Currently, the drug is in the Phase II stage of development to treat Diabetes.

XW014: Sciwind Biosciences

XW014 is an oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist developed by Sciwind Biosciences for the treatment of obesity and Diabetes (T2D). XW014 functions as a GLP-1 receptor agonist, which means it mimics the action of the GLP-1 hormone that is released after meals. This hormone plays a key role in regulating glucose metabolism by stimulating insulin secretion, inhibiting glucagon release, and promoting satiety. As an oral small molecule, XW014 offers advantages over traditional peptide-based GLP-1 therapies, such as ease of administration and the potential for combination therapies with other oral medications. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diabetes.

KN056: Suzhou Alphamab Co., Ltd.

KN-056 is a glucagon-like peptide-1 receptor (GLP-1R) modulator developed by Suzhou Alphamab Co., Ltd. for the treatment of Diabetes. KN-056 functions as a GLP-1R modulator, which means it targets the glucagon-like peptide-1 receptor. GLP-1 is a hormone that plays a key role in regulating glucose metabolism by stimulating insulin secretion, inhibiting glucagon release, and promoting satiety. By modulating the GLP-1 receptor, KN-056 aims to improve glycemic control in patients with Diabetes. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diabetes.

Diabetes: Therapeutic Assessment

This segment of the report provides insights about the different Diabetes drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Diabetes

• There are approx. 200+ key companies which are developing the therapies for Diabetes. The companies which have their Diabetes drug candidates in the most advanced stage, i.e. Phase III include, vTv Therapeutics, Eli Lilly and Company and Tonghua Dongbao Pharmaceutical.

Phases

The report covers around 200+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Diabetes: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetes therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetes drugs.

Diabetes Report Insights

• Diabetes Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Diabetes Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Diabetes drugs?
• How many Diabetes drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetes?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Diabetes therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Diabetes and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• vTv Therapeutics
• Tonghua Dongbao Pharmaceutical
• Eli Lilly and Company
• Celon Pharma
• Sciwind Biosciences
• AstraZeneca
• Suzhou Alphamab Co., Ltd.
• Neurodon
• Abarceo Pharma
• Chong Kun Dang Pharmaceutical

Key Products

• Cadisegliatin
• THDB0206
• LY-3209590
• CPL207280
• XW014
• ECC5004
• KN056
• RGT001-075
• NRDN-101

Research programme: Diabetes mellitus therapeutics

• CKD-383

This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.